التداخل بين ديلتيازيم وزيبراسيدون

Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications).

• Because of its potential for inducing hypotension, ziprasidone may enhance the effects of certain antihypertensive agents.

Ketoconazole Ketoconazole, a potent inhibitor of CYP3A4, at a dose of 400 mg QD for 5 days, increased the AUC and C max of ziprasidone by about 35 to 40%.

Other inhibitors of CYP3A4 would be expected to have similar effects.